Elkin Garcia-Cifuentes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elkin Garcia-Cifuentes has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Jaramillo-Jimenez
Centre for Age‐related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway
4 shared publications Angela Iragorri
Neurology Unit, Department of Neuroscience, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Semillero de Neurociencias y Envejecimiento, Ageing Institute, Medical School, Pontificia Universidad Javeriana, Bogotá, Colombia
4 shared publicationsFrancisco Lopera
Facultad de Medicina, Semillero de Neurociencias y Envejecimiento, Instituto de Envejecimiento, Pontificia Universidad Javeriana, Bogotá, Colombia
4 shared publications- Daniel Vasquez
Universidad de Antioquía
3 shared publications - David Aguillon
Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
3 shared publications David Fernando Aguillón Niño
Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Antioquia, Colombia
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
Ataxic variant of sporadic Creutzfeldt-Jakob disease with predominant basal ganglia involvement: Case report and review of molecular classification and their MRI patterns
Introduction: Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder caused by the accumulation of misfolded prion proteins. Molecular classification, based on PRNP codon 129 polymorphisms and the protease-resistant PrPsc fragment, has refined recognition of subtypes and their correlation with specific neuroimaging patterns. Case presentation: We report a 60-year-old patient presenting with progressive instability, lateral propulsion, generalized polymyoclonus, tremors, paranoid delusions, and vivid hallucinations. Prominent cerebellar signs and gait disturbance were dominant, configuring an ataxic phenotype accompanied by cognitive decline. An extensive workup excluded alternative diagnoses, and the detection of 14-3-3 protein in cerebrospinal fluid, along with positive RT-QuIC and diffusion-weighted magnetic resonance imaging (MRI) findings, were compatible with probable sporadic CJD. Remarkably, the MRI revealed an atypical pattern with predominant basal ganglia involvement rather than the common cortical changes, raising MV2K as a radiological hypothesis and underscoring the clinical-radiological heterogeneity of the ataxic presentation. Discussion: CJD has diverse phenotypic variants. Molecular classification and advanced MRI techniques, particularly diffusion-weighted imaging (DWI), are crucial for distinguishing between sporadic subtypes. Identifying atypical presentations, such as ataxic variants with basal ganglia predominance, improves premortem diagnostic certainty in resource-limited settings where molecular subtyping is not widely available. Conclusion: Molecular and neuroimaging-based approaches have substantially deepened the understanding of CJD heterogeneity. This case emphasizes the value of DWI/MRI in identifying atypical ataxic variants and reinforces the importance of integrating biomarker-supported diagnosis and clinical-radiological correlation when approaching this disease.
- 16 June 2026
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
Open AccessAtaxic variant of sporadic Creutzfeldt-Jakob disease with predominant basal ganglia involvement: Case report and review of molecular classification and their MRI patterns
Introduction: Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder caused by the accumulation of misfolded prion proteins. Molecular classification, based on PRNP codon 129 polymorphisms and the protease-resistant PrPsc fragment, has refined recognition of subtypes and their correlation with specific neuroimaging patterns. Case presentation: We report a 60-year-old patient presenting with progressive instability, lateral propulsion, generalized polymyoclonus, tremors, paranoid delusions, and vivid hallucinations. Prominent cerebellar signs and gait disturbance were dominant, configuring an ataxic phenotype accompanied by cognitive decline. An extensive workup excluded alternative diagnoses, and the detection of 14-3-3 protein in cerebrospinal fluid, along with positive RT-QuIC and diffusion-weighted magnetic resonance imaging (MRI) findings, were compatible with probable sporadic CJD. Remarkably, the MRI revealed an atypical pattern with predominant basal ganglia involvement rather than the common cortical changes, raising MV2K as a radiological hypothesis and underscoring the clinical-radiological heterogeneity of the ataxic presentation. Discussion: CJD has diverse phenotypic variants. Molecular classification and advanced MRI techniques, particularly diffusion-weighted imaging (DWI), are crucial for distinguishing between sporadic subtypes. Identifying atypical presentations, such as ataxic variants with basal ganglia predominance, improves premortem diagnostic certainty in resource-limited settings where molecular subtyping is not widely available. Conclusion: Molecular and neuroimaging-based approaches have substantially deepened the understanding of CJD heterogeneity. This case emphasizes the value of DWI/MRI in identifying atypical ataxic variants and reinforces the importance of integrating biomarker-supported diagnosis and clinical-radiological correlation when approaching this disease.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e105868
Muscle Function and Cognitive Performance in Autosomal Dominant AlzheimerDisease Insights from the PSEN1‐E280A Colombian Kindred
Background: Carriers of the PSEN1‐E280A variant, the largest known autosomal dominant Alzheimer's disease (ADAD) cohort, typically experience mild cognitive impairment by age 44 and dementia by 49. Emerging evidence suggests gait speed (GS) may be an early marker of cognitive decline. While past research focused on older adults, recent studies explore muscle decline in younger individuals. This study examines the relationship between GS and cognition within the Colombian PSEN1‐E280A cohort. Method: The study included 134 individuals from families affected by early‐onset ADAD with the PSEN1 gene variant. Among them, 66 were carriers (including 5 with mild cognitive impairment and 5 with dementia), while 68 were non‐carriers. The participants had a mean age of 32 years (SD = 8.72), with 49.3% being male. Cognitively‐unimpaired status was defined by Functional Assessment Staging (FAST) scores p = 0.307). On the MMSE, all carriers scored an average of 26.55 (SD = 4.56), while non‐carriers scored 28.81 (SD = 1.24), a statistically significant difference ( p < 0.001). GS was significantly slower in the cognitively‐impaired group compared to cognitively‐unimpaired group (1.37 m/s vs. 1.63 m/s; p = 0.042). Pearson correlation analysis revealed a weak positive correlation between GS and MMSE ( r = 0.18; p = 0.041), with this effect being more pronounced in the impaired group. Conclusion: Our findings show that single‐task GS does not differentiate young individuals with ADAD due to PSEN1‐E280A but is significantly associated with global cognitive function, particularly in cognitively‐impaired individuals. This suggests that gait impairments emerge as cognitive decline progresses, consistent with findings in sporadic Alzheimer's disease, where motor dysfunction often appears in early symptomatic stages. These results reinforce the link between motor decline and cognitive impairment. Further research is needed to explore the interplay between cognitive and physical performance in this population.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e105868
Open AccessMuscle Function and Cognitive Performance in Autosomal Dominant AlzheimerDisease Insights from the PSEN1‐E280A Colombian Kindred
Background: Carriers of the PSEN1‐E280A variant, the largest known autosomal dominant Alzheimer's disease (ADAD) cohort, typically experience mild cognitive impairment by age 44 and dementia by 49. Emerging evidence suggests gait speed (GS) may be an early marker of cognitive decline. While past research focused on older adults, recent studies explore muscle decline in younger individuals. This study examines the relationship between GS and cognition within the Colombian PSEN1‐E280A cohort. Method: The study included 134 individuals from families affected by early‐onset ADAD with the PSEN1 gene variant. Among them, 66 were carriers (including 5 with mild cognitive impairment and 5 with dementia), while 68 were non‐carriers. The participants had a mean age of 32 years (SD = 8.72), with 49.3% being male. Cognitively‐unimpaired status was defined by Functional Assessment Staging (FAST) scores p = 0.307). On the MMSE, all carriers scored an average of 26.55 (SD = 4.56), while non‐carriers scored 28.81 (SD = 1.24), a statistically significant difference ( p < 0.001). GS was significantly slower in the cognitively‐impaired group compared to cognitively‐unimpaired group (1.37 m/s vs. 1.63 m/s; p = 0.042). Pearson correlation analysis revealed a weak positive correlation between GS and MMSE ( r = 0.18; p = 0.041), with this effect being more pronounced in the impaired group. Conclusion: Our findings show that single‐task GS does not differentiate young individuals with ADAD due to PSEN1‐E280A but is significantly associated with global cognitive function, particularly in cognitively‐impaired individuals. This suggests that gait impairments emerge as cognitive decline progresses, consistent with findings in sporadic Alzheimer's disease, where motor dysfunction often appears in early symptomatic stages. These results reinforce the link between motor decline and cognitive impairment. Further research is needed to explore the interplay between cognitive and physical performance in this population.
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103932
Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease
Background: Colombia hosts the largest Autosomal‐Dominant Alzheimer's Disease (ADAD) kindred caused by the PSEN1‐E280A genetic variant, with full penetrance. This ADAD is well‐characterized in terms of clinical and biomarker research, but Electroencephalography (EEG) as a biomarker is still under development. EEG facilitates understanding brain function and electrophysiological changes in ADAD. Dual‐task (DT) paradigms, particularly during gait and upper extremity function, are useful biomarkers to determine cognitive impairments, due to neurodegenerative disorders such as Alzheimer's disease. EEG and DT are non‐invasive, portable, and feasible in outpatient settings, making them highly accessible for clinical practice. Method: The study sample includes two groups, asymptomatic carriers ( n = 37) and non‐carriers ( n = 42) of the PSEN1‐E280A variant. EEG data were recorded during a dual‐task paradigm involving two tasks. The first task was a motor task (single‐task) involving upper extremity flexion‐extension. The second was a motor‐cognitive task (dual‐task), which included subtraction by 7 (DTS7), by 1 (DTS1) or verbal fluency with animals (DTAN). EEG signals were collected using the OpenBCI system from frontal and central regions. Data were processed and spectral and neural dynamics features were extracted. Dual‐task cost (DTC) was calculated as the difference between metric values under dual‐task and single‐task conditions, computed across channels and frequency bands for each feature. The extracted metrics were statistically analyzed using Cohen's‐D effect size and Mann‐Whitney U‐tests to assess differences. Result: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha‐1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. Conclusion: The proposed experiment effectively extracted brain information that differentiates between carriers and non‐carriers of the PSEN1‐E280A variant. DTC values in the alpha band (frontal and central regions) and the beta band (central regions) exhibited larger effect sizes, suggesting that these areas are sensitive to preclinical cognitive and motor differences. The experimental paradigm and data‐processing pipeline ensured the acquisition of EEG data with meaningful neurological information. This combination of novel biomarkers enhances non‐invasive and portable tools for identifying ADAD carriers during preclinical stages.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S2) , e103932
Open AccessQuantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease
Background: Colombia hosts the largest Autosomal‐Dominant Alzheimer's Disease (ADAD) kindred caused by the PSEN1‐E280A genetic variant, with full penetrance. This ADAD is well‐characterized in terms of clinical and biomarker research, but Electroencephalography (EEG) as a biomarker is still under development. EEG facilitates understanding brain function and electrophysiological changes in ADAD. Dual‐task (DT) paradigms, particularly during gait and upper extremity function, are useful biomarkers to determine cognitive impairments, due to neurodegenerative disorders such as Alzheimer's disease. EEG and DT are non‐invasive, portable, and feasible in outpatient settings, making them highly accessible for clinical practice. Method: The study sample includes two groups, asymptomatic carriers ( n = 37) and non‐carriers ( n = 42) of the PSEN1‐E280A variant. EEG data were recorded during a dual‐task paradigm involving two tasks. The first task was a motor task (single‐task) involving upper extremity flexion‐extension. The second was a motor‐cognitive task (dual‐task), which included subtraction by 7 (DTS7), by 1 (DTS1) or verbal fluency with animals (DTAN). EEG signals were collected using the OpenBCI system from frontal and central regions. Data were processed and spectral and neural dynamics features were extracted. Dual‐task cost (DTC) was calculated as the difference between metric values under dual‐task and single‐task conditions, computed across channels and frequency bands for each feature. The extracted metrics were statistically analyzed using Cohen's‐D effect size and Mann‐Whitney U‐tests to assess differences. Result: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha‐1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. Conclusion: The proposed experiment effectively extracted brain information that differentiates between carriers and non‐carriers of the PSEN1‐E280A variant. DTC values in the alpha band (frontal and central regions) and the beta band (central regions) exhibited larger effect sizes, suggesting that these areas are sensitive to preclinical cognitive and motor differences. The experimental paradigm and data‐processing pipeline ensured the acquisition of EEG data with meaningful neurological information. This combination of novel biomarkers enhances non‐invasive and portable tools for identifying ADAD carriers during preclinical stages.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S9) , e110642
Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease
Background: Colombia hosts the largest Autosomal‐Dominant Alzheimer's Disease (ADAD) kindred caused by the PSEN1‐E280A genetic variant, with full penetrance. This ADAD is well‐characterized in terms of clinical and biomarker research, but Electroencephalography (EEG) as a biomarker is still under development. EEG facilitates understanding brain function and electrophysiological changes in ADAD. Dual‐task (DT) paradigms, particularly during gait and upper extremity function, are useful biomarkers to determine cognitive impairments, due to neurodegenerative disorders such as Alzheimer's disease. EEG and DT are non‐invasive, portable, and feasible in outpatient settings, making them highly accessible for clinical practice. Method: The study sample includes two groups, asymptomatic carriers ( n = 37) and non‐carriers ( n = 42) of the PSEN1‐E280A variant. EEG data were recorded during a dual‐task paradigm involving two tasks. The first task was a motor task (single‐task) involving upper extremity flexion‐extension. The second was a motor‐cognitive task (dual‐task), which included subtraction by 7 (DTS7), by 1 (DTS1) or verbal fluency with animals (DTAN). EEG signals were collected using the OpenBCI system from frontal and central regions. Data were processed and spectral and neural dynamics features were extracted. Dual‐task cost (DTC) was calculated as the difference between metric values under dual‐task and single‐task conditions, computed across channels and frequency bands for each feature. The extracted metrics were statistically analyzed using Cohen's‐D effect size and Mann‐Whitney U‐tests to assess differences. Result: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha‐1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. Conclusion: The proposed experiment effectively extracted brain information that differentiates between carriers and non‐carriers of the PSEN1‐E280A variant. DTC values in the alpha band (frontal and central regions) and the beta band (central regions) exhibited larger effect sizes, suggesting that these areas are sensitive to preclinical cognitive and motor differences. The experimental paradigm and data‐processing pipeline ensured the acquisition of EEG data with meaningful neurological information. This combination of novel biomarkers enhances non‐invasive and portable tools for identifying ADAD carriers during preclinical stages.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S9) , e110642
Open AccessQuantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease
Background: Colombia hosts the largest Autosomal‐Dominant Alzheimer's Disease (ADAD) kindred caused by the PSEN1‐E280A genetic variant, with full penetrance. This ADAD is well‐characterized in terms of clinical and biomarker research, but Electroencephalography (EEG) as a biomarker is still under development. EEG facilitates understanding brain function and electrophysiological changes in ADAD. Dual‐task (DT) paradigms, particularly during gait and upper extremity function, are useful biomarkers to determine cognitive impairments, due to neurodegenerative disorders such as Alzheimer's disease. EEG and DT are non‐invasive, portable, and feasible in outpatient settings, making them highly accessible for clinical practice. Method: The study sample includes two groups, asymptomatic carriers ( n = 37) and non‐carriers ( n = 42) of the PSEN1‐E280A variant. EEG data were recorded during a dual‐task paradigm involving two tasks. The first task was a motor task (single‐task) involving upper extremity flexion‐extension. The second was a motor‐cognitive task (dual‐task), which included subtraction by 7 (DTS7), by 1 (DTS1) or verbal fluency with animals (DTAN). EEG signals were collected using the OpenBCI system from frontal and central regions. Data were processed and spectral and neural dynamics features were extracted. Dual‐task cost (DTC) was calculated as the difference between metric values under dual‐task and single‐task conditions, computed across channels and frequency bands for each feature. The extracted metrics were statistically analyzed using Cohen's‐D effect size and Mann‐Whitney U‐tests to assess differences. Result: The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha‐1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task. Conclusion: The proposed experiment effectively extracted brain information that differentiates between carriers and non‐carriers of the PSEN1‐E280A variant. DTC values in the alpha band (frontal and central regions) and the beta band (central regions) exhibited larger effect sizes, suggesting that these areas are sensitive to preclinical cognitive and motor differences. The experimental paradigm and data‐processing pipeline ensured the acquisition of EEG data with meaningful neurological information. This combination of novel biomarkers enhances non‐invasive and portable tools for identifying ADAD carriers during preclinical stages.
- Open Access
- 2 October 2025
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 41 (4)
Non-motor symptoms in Parkinson's disease: Recognition, diagnosis, and implications for comprehensive management
Introduction: Parkinson’s disease (PD) is traditionally defined by motor symptoms such as bradykinesia, rigidity, and tremors. However, non-motor symptoms (NMS) are now recognized as central contributors to disability, often preceding motor onset and remaining underdiagnosed. Materials and methods: This narrative review is based on a focused literature analysis of non-motor symptoms in Parkinson’s disease, including neuropsychiatric, cognitive, sensory, sleep, and autonomic domains. Articles were selected for clinical relevance and pathophysiological insights. Results: The reviewed literature indicates that non-motor symptoms are highly prevalent and significantly impact quality of life in Parkinson’s disease. These symptoms often correlate with disease progression and motor fluctuations. Various management strategies have been described, although underdiagnosis remains common due to limited screening in routine clinical practice. Conclusions: Early identification and targeted treatment of non-motor symptoms are critical for optimizing clinical outcomes, improving patient quality of life, and reducing healthcare burdens. Comprehensive clinical assessments and the integration of multidisciplinary care models are essential to meet the complex needs of patients with Parkinson’s disease.
- 2 October 2025
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 41 (4)
Open AccessNon-motor symptoms in Parkinson's disease: Recognition, diagnosis, and implications for comprehensive management
Introduction: Parkinson’s disease (PD) is traditionally defined by motor symptoms such as bradykinesia, rigidity, and tremors. However, non-motor symptoms (NMS) are now recognized as central contributors to disability, often preceding motor onset and remaining underdiagnosed. Materials and methods: This narrative review is based on a focused literature analysis of non-motor symptoms in Parkinson’s disease, including neuropsychiatric, cognitive, sensory, sleep, and autonomic domains. Articles were selected for clinical relevance and pathophysiological insights. Results: The reviewed literature indicates that non-motor symptoms are highly prevalent and significantly impact quality of life in Parkinson’s disease. These symptoms often correlate with disease progression and motor fluctuations. Various management strategies have been described, although underdiagnosis remains common due to limited screening in routine clinical practice. Conclusions: Early identification and targeted treatment of non-motor symptoms are critical for optimizing clinical outcomes, improving patient quality of life, and reducing healthcare burdens. Comprehensive clinical assessments and the integration of multidisciplinary care models are essential to meet the complex needs of patients with Parkinson’s disease.
- 2 July 2025
- Published by Elsevier in Neuroscience
- Vol. 581, 26-33
Autoimmune encephalitis in an underrepresented population: A case series from 2018 to 2023 in Bogotá, Colombia
- 2 July 2025
- Published by Elsevier in Neuroscience
- Vol. 581, 26-33
Autoimmune encephalitis in an underrepresented population: A case series from 2018 to 2023 in Bogotá, Colombia
- Open Access
- 1 December 2022
- Published by Springer Nature in Research Square
Rapidly progressive dementia with an atypical presentation of rigid-akinetic syndrome caused by Cryptococcus Gattii: A case report
Background Meningoencephalitis by Cryptococcus gattii (C. gattii) can be responsible for unspecific neurological clinical features, and its lesions in the brain can be diffuse with a preference for basal ganglia. Case presentation Here we describe the case of a 72- year-old woman who developed dementia and akinetic rigid syndrome with bilateral hand myoclonus in six-month period. Brain magnetic resonance imaging revealed striking leptomeningeal compromise and lesions in the midbrain. Film array and culture for C. gattii in cerebrospinal fluid were positive and she was diagnosed with meningoencephalitis by C. gattii. Antifungal management with amphotericin B plus flucytosine was started, and induction therapy was proposed for 4 to 6 weeks. Conclusions Our case showed that meningoencephalitis by C. gattii associated with rapidly progressive dementia, gait disturbance and a pseudo-parinaud syndrome could be an atypical clinical presentation of meningoencephalitis by cryptococcus.
- 1 December 2022
- Published by Springer Nature in Research Square
Open AccessRapidly progressive dementia with an atypical presentation of rigid-akinetic syndrome caused by Cryptococcus Gattii: A case report
Background Meningoencephalitis by Cryptococcus gattii (C. gattii) can be responsible for unspecific neurological clinical features, and its lesions in the brain can be diffuse with a preference for basal ganglia. Case presentation Here we describe the case of a 72- year-old woman who developed dementia and akinetic rigid syndrome with bilateral hand myoclonus in six-month period. Brain magnetic resonance imaging revealed striking leptomeningeal compromise and lesions in the midbrain. Film array and culture for C. gattii in cerebrospinal fluid were positive and she was diagnosed with meningoencephalitis by C. gattii. Antifungal management with amphotericin B plus flucytosine was started, and induction therapy was proposed for 4 to 6 weeks. Conclusions Our case showed that meningoencephalitis by C. gattii associated with rapidly progressive dementia, gait disturbance and a pseudo-parinaud syndrome could be an atypical clinical presentation of meningoencephalitis by cryptococcus.
- Open Access
- 13 May 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (7) , 1549-1556
A nutritionally focused program for community-living older adults resulted in improved health and well-being
- 13 May 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (7) , 1549-1556
Open AccessA nutritionally focused program for community-living older adults resulted in improved health and well-being
- Open Access
- 1 April 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 8, 100162
Motoric Cognitive Risk Syndrome: Prevalence and Cognitive Performance. A cross-sectional study
- 1 April 2022
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 8, 100162
Open AccessMotoric Cognitive Risk Syndrome: Prevalence and Cognitive Performance. A cross-sectional study
- Open Access
- 18 February 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 695253
Muscular Function as an Alternative to Identify Cognitive Impairment: A Secondary Analysis From SABE Colombia
Background: Identification of cognitive impairment is based traditionally on the neuropsychological tests and biomarkers that are not available widely. This study aimed to establish the association between motor function (gait speed and handgrip strength) and cognitive performance in the Mini-Mental State Examination, globally and by domains. A secondary goal was calculating a cut-off point for gait speed and handgrip strength to classify older adults as cognitively impaired.Methods: This is a secondary analysis of SABE Colombia (Salud, Bienestar & Envejecimiento), a survey that was conducted in 2015 on health, wellbeing, and aging in Colombia. This study used linear regression models to search for an association between motor function and cognitive performance. The accuracy of motor function measurements in identifying cognitive impairment was assessed with receiver operating characteristic (ROC) curves. This study also analyzed other clinical and sociodemographical variables.Results: Gait speed was associated with orientation (r2 = 0.16), language (r2 = 0.15), recall memory (r2 = 0.14), and counting (r2 = 0.08). Similarly, handgrip strength was associated with orientation (r2 = 0.175), language (r2 = 0.164), recall memory (r2 = 0.137), and counting (r2 = 0.08). To differentiate older adults with and without cognitive impairment, a gait speed cut-off point of 0.59 m/s had an area under the curve (AUC) of 0.629 (0.613–0.646), and a weak handgrip (strength below 17.5 kg) had an AUC of 0.653 (0.645-0.661). The cut-off points for handgrip strength and gait speed were significantly higher in male participants.Conclusions: Gait speed and handgrip strength are similarly associated with the cognitive performance, exhibiting the most extensive association with orientation and language domains of the Mini-Mental State Examination. Gait speed and handgrip strength can easily be measured by any clinician, and they prove to be useful screening tools to detect cognitive impairment.
- 18 February 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 695253
Open AccessMuscular Function as an Alternative to Identify Cognitive Impairment: A Secondary Analysis From SABE Colombia
Background: Identification of cognitive impairment is based traditionally on the neuropsychological tests and biomarkers that are not available widely. This study aimed to establish the association between motor function (gait speed and handgrip strength) and cognitive performance in the Mini-Mental State Examination, globally and by domains. A secondary goal was calculating a cut-off point for gait speed and handgrip strength to classify older adults as cognitively impaired.Methods: This is a secondary analysis of SABE Colombia (Salud, Bienestar & Envejecimiento), a survey that was conducted in 2015 on health, wellbeing, and aging in Colombia. This study used linear regression models to search for an association between motor function and cognitive performance. The accuracy of motor function measurements in identifying cognitive impairment was assessed with receiver operating characteristic (ROC) curves. This study also analyzed other clinical and sociodemographical variables.Results: Gait speed was associated with orientation (r2 = 0.16), language (r2 = 0.15), recall memory (r2 = 0.14), and counting (r2 = 0.08). Similarly, handgrip strength was associated with orientation (r2 = 0.175), language (r2 = 0.164), recall memory (r2 = 0.137), and counting (r2 = 0.08). To differentiate older adults with and without cognitive impairment, a gait speed cut-off point of 0.59 m/s had an area under the curve (AUC) of 0.629 (0.613–0.646), and a weak handgrip (strength below 17.5 kg) had an AUC of 0.653 (0.645-0.661). The cut-off points for handgrip strength and gait speed were significantly higher in male participants.Conclusions: Gait speed and handgrip strength are similarly associated with the cognitive performance, exhibiting the most extensive association with orientation and language domains of the Mini-Mental State Examination. Gait speed and handgrip strength can easily be measured by any clinician, and they prove to be useful screening tools to detect cognitive impairment.